original ) (raw )Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
Neal Thomas
Biologics Targets Therapy, 2007
View PDFchevron_right
Palivizumab in the prophylaxis of respiratory syncytial virus infection
silvia cardenas
Expert Review of Anti-infective Therapy, 2005
View PDFchevron_right
Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
Asunción Mejías
Biologics: targets & therapy, 2008
View PDFchevron_right
A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the
Konstantin Gudkov
2012
View PDFchevron_right
Palivizumab Prophylaxis of Respiratory Syncytial Virus Infection in High‐Risk Infants: A Note of Caution
Laurie Debonnett
Journal of Paediatrics and Child Health, 2003
View PDFchevron_right
Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalizations for respiratory syncytial virus in infants
Meri Gorgievski-hrisoho , Andrea Duppenthaler
Swiss medical weekly: official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology
View PDFchevron_right
Regional impact of prophylaxis with the monoclonal antibody palivizumab on ospitalizations from respiratory syncytial virus in infants
Andrea Duppenthaler
Swiss Medical Weekly, 2001
View PDFchevron_right
Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants
Meri Gorgievski-Hrisoho
Swiss medical weekly, 2001
View PDFchevron_right
A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation
Konstantin Gudkov
BMC Research Notes, 2012
View PDFchevron_right
Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants
Copley Forbes
Human vaccines & immunotherapeutics, 2014
View PDFchevron_right
Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review
Lim Kai Toh
View PDFchevron_right
A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
brian harris
BMC Pediatrics, 2010
View PDFchevron_right
Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit
Daniel Virella
Journal of Hospital Infection, 2004
View PDFchevron_right
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
Bruno Baršić
Evidence-Based Child Health: A Cochrane Review Journal, 2013
View PDFchevron_right
Respiratory syncytial virus prophylaxis—the story so far
Jessie Groothuis
Respiratory Medicine, 2002
View PDFchevron_right
Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention
Val Hemming
Advances in Therapy, 2011
View PDFchevron_right
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Sinsi Hernández-Cancio
PEDIATRICS
View PDFchevron_right
Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV
Jessie Groothuis
Journal of Infection and Chemotherapy, 2002
View PDFchevron_right
Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis
L. Lehtonen , Terho Heikkinen
Archives of Disease in Childhood - Fetal and Neonatal Edition, 2005
View PDFchevron_right
Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals
Sonia Saxena
Archives of Disease in Childhood, 2014
View PDFchevron_right
Respiratory Syncytial Virus (RSV) Prevention 2012
Raylene Phillips
Neonatology
View PDFchevron_right
A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection
Joseph Beyene
BMC infectious …, 2009
View PDFchevron_right
A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS
Abby Li
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012
View PDFchevron_right
Beyond randomized controlled trials: A “real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab
Ian Mitchell
Pediatric Pulmonology, 2006
View PDFchevron_right
Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-analysis
Robert Welliver
Pediatric Critical Care Medicine, 2011
View PDFchevron_right
Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus
Louis Saravolatz
Clinical Infectious Diseases, 2010
View PDFchevron_right
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
Nusrat Homaira
International Journal of Pediatrics, 2014
View PDFchevron_right
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis
Dan Stewart
Journal of managed care pharmacy : JMCP
View PDFchevron_right
An update of the recommendations of the spanish neonatology society for the use of paivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants
Cèsar W. Ruiz-Campillo
Anales de Pediatría (English Edition), 2019
View PDFchevron_right
Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
Dr. Khaled El-Atawi
Canadian Respiratory Journal, 2019
View PDFchevron_right
Palivizumab for preventing respiratory syncytial virus (RSV) infection in children
CAMILA MICAELA ESCOBAR LIQUITAY
Cochrane Database of Systematic Reviews, 2020
View PDFchevron_right